American Association for Cancer Research
ccr-24-0148_supplementary_figure_s1_suppfs1.pdf (327.14 kB)

Supplementary Figure S1 from Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma

Download (327.14 kB)
journal contribution
posted on 2024-05-15, 07:20 authored by Josephine K. Dermawan, Sarah Chiang, Samuel Singer, Bhumika Jadeja, Martee L. Hensley, William D. Tap, Sujana Movva, Robert G. Maki, Cristina R. Antonescu

Supplementary Figure S1. A. Lollipop plots depicting the distribution of point mutations in TP53, RB1 and ATRX in STLMS and ULMS. B-C. Oncoprints in STLMS (B) and ULMS (C) depicting the distribution of recurrent genetic alterations in primary versus metastatic samples (unpaired).


National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Cycle for Survival

Suzie Wolf Coffland Fund

Kristin Ann Carr Foundation



Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous tumors. Despite recent large-scale genomic studies, current LMS risk stratification is not informed by molecular alterations. We propose a clinically applicable genomic risk stratification model. We performed comprehensive genomic profiling in a cohort of 195 soft tissue LMS (STLMS), 151 primary at presentation, and a control group of 238 uterine LMS (ULMS), 177 primary at presentation, with at least 1-year follow-up. In STLMS, French Federation of Cancer Centers (FNCLCC) grade but not tumor size predicted progression-free survival (PFS) or disease-specific survival (DSS). In contrast, in ULMS, tumor size, mitotic rate, and necrosis were associated with inferior PFS and DSS. In STLMS, a 3-tier genomic risk stratification performed well for DSS: high risk: co-occurrence of RB1 mutation and chr12q deletion (del12q)/ATRX mutation; intermediate risk: presence of RB1 mutation, ATRX mutation, or del12q; low risk: lack of any of these three alterations. The ability of RB1 and ATRX alterations to stratify STLMS was validated in an external AACR GENIE cohort. In ULMS, a 3-tier genomic risk stratification was significant for both PFS and DSS: high risk: concurrent TP53 mutation and chr20q amplification/ATRX mutations; intermediate risk: presence of TP53 mutation, ATRX mutation, or amp20q; low risk: lack of any of these three alterations. Longitudinal sequencing showed that most molecular alterations were early clonal events that persisted during disease progression. Compared with traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.

Usage metrics

    Clinical Cancer Research



    Ref. manager